Track record · closed signal

Pfizer Inc. (PFE) — closed signal from February 27, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 28, 2026 — -3.6% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$26.50 – $27.40Entry zone — fair-value band

$27.13Published — price the day we called it

$30.92Target — the price the thesis aimed for

$28.75Peak — highest point inside the window, not a realized return

$26.14Window close — end-of-window price, context only

What happened

Partial

Reached 43% of the predicted growth at its peak, without hitting the target.

At window close

-3.6%

realized, from the publication price to the last close inside the window

Peak gain

+6%

peak, from the publication price — not a realized return

S&P 500, same window

+10.3%

SPY over the identical days, dividend-adjusted

Window close

$26.14

last close inside the window, ended May 28, 2026

Peak price

$28.75

peak on April 2, 2026 — not a realized return

Days to target

—

The thesis — published February 27, 2026

Predicted growth

+14%

over the measurement window

Target price

$30.92

the price the thesis aimed for

Entry zone

$26.50 – $27.40

the fair-value band we waited for

Price at publication

$27.13

published February 27, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer just got full FDA approval for a cancer drug, which can change how investors feel about the stock over the next few weeks. The company is coming off a long down period and now sits in a quieter price area where buyers can enter without chasing big gains. The main risk is that the initial excitement fades or the drug doesn't drive steady demand.

Primary drivers

FDA approval for BRAFTOVI can renew investor interest
Being a large, established drug company helps steady demand
Current base gives a clearer level to place buys and limits loss
Future gains need ongoing demand after the approval

How it played out

PFE: target stayed out of reach

Lyra published PFE at $27.13 on 2026-02-27 for a short-term window ending 2026-05-28. The thesis expected 14% growth and pointed to full FDA approval for BRAFTOVI, Pfizer's scale as an established drug company, a quieter price area for entry, and the need for demand after the approval to keep gains going.

Inside the window, PFE rose to a peak of $28.75 on 2026-04-02, a 6% gain. It stayed below the $30.92 target. By 2026-05-28, it ended at $26.14. The thesis partially played out early, but the target was missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals